Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Neuroscience Antibodies & Assays Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The neuroscience antibodies & assays market has experienced substantial expansion in recent years. This market is projected to increase from $5.03 billion in 2025 to $5.76 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.5%. The historical growth can be attributed to the rising prevalence of neurological disorders, expansion of neuroscience research funding, increased use of immunoassays in diagnostics, availability of advanced laboratory instruments, and the growth of academic neuroscience programs.
The neuroscience antibodies & assays market size is anticipated to undergo significant expansion over the next few years, with projections indicating it will reach $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. This anticipated rise during the forecast period is fueled by several factors, including increasing investments in neurodegenerative disease research, a growing demand for personalized neurology diagnostics, the expansion of drug discovery programs, rising adoption of automated assay platforms, and an enhanced focus on early disease detection. Key developments expected during this period involve the increasing adoption of high-specificity antibody reagents, greater use of multiplex assay platforms, growing integration of automation in neuro research labs, the expansion of biomarker-based neurological studies, and an increased emphasis on reproducibility and sensitivity.
Get A Free Sample Report With In-Depth Market Insights:
Neuroscience Antibodies & Assays Market Growth Drivers: What’s Behind The Acceleration?
The rising occurrence of neurological conditions is anticipated to fuel the expansion of the neuroscience antibodies and assays market. Neurological illnesses are defined as disorders impacting the brain, spinal cord, and nerves, leading to diminished cognitive, motor, or sensory capabilities. The escalating frequency of neurological illnesses is primarily attributable to an aging global population, as the increasing number of seniors in developed nations contributes to a higher prevalence of age-related conditions such as Alzheimer’s disease and Parkinson’s disease. This growing number of neurological illness incidents boosts the need for specialized antibodies and assays because researchers and clinicians depend on these diagnostic and research instruments to identify, investigate, and track disease-specific biomarkers and protein anomalies present in neurological disorders. For example, data from March 2023, provided by the Alzheimer’s Association, a US-based nonprofit voluntary health organization, indicates that in 2023, approximately 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, a figure expected to escalate to 13.8 million by 2060. Consequently, the increased occurrence of neurological illnesses is propelling the expansion of the neuroscience antibodies and assays market.
Neuroscience Antibodies & Assays Market Segments: Where Is Growth Concentrated?
The neuroscience antibodies & assays market covered in this report is segmented –
1) By Product: Consumables, Instruments
2) By Technology: Molecular Diagnostics, Immunoassays Or Immunochemistry, Other Technologies
3) By Application: In Vitro Diagnostics, Research, Drug Discovery
4) By End User: Hospitals And Diagnostics Centers, Academic And Research Institutes, Pharmaceutical And Biotechnology Companies
Subsegments:
1) By Consumables: Antibodies, Assay Kits
2) By Instruments: Spectrophotometers, Microplate Readers, Flow Cytometers, Western Blotting Systems, Imaging Systems, Automated Workstations
Neuroscience Antibodies & Assays Market Trends: What’s Defining The Industry’s Next Phase?
Major companies operating in the neuroscience antibodies and assays market are focusing on developing innovative products, such as bispecific in vivo–ready antibodies, to simultaneously target multiple neurological pathways for more precise and effective research outcomes. These bispecific in vivo–ready antibodies are engineered to bind two different targets simultaneously and are formulated for use in live animal models, helping researchers modulate multiple neurological pathways at once for more precise and physiologically relevant neuroscience studies. For instance, in October 2025, Bio X Cell LLC, a US–based biotechnology company, launched an expanded catalog of bispecific and ADC (antibody-drug conjugate) antibodies as part of its refreshed brand identity, targeting advanced preclinical neuroscience and translational research applications. These bispecific antibodies are engineered to bind two distinct antigens simultaneously, allowing researchers to modulate multiple signaling pathways or cell populations in the brain within a single study, unlike traditional monoclonal antibodies that target only one molecule. They are produced with high purity (= 95%) and ultra-low endotoxin levels (= 0.5 EU/mg), making them suitable for sensitive in vivo experiments, organoid models, and organ-on-chip systems. The ADCs combine a functional antibody with a cytotoxic payload to selectively target specific neuronal or glial populations, offering precise modulation and experimental flexibility.
Neuroscience Antibodies & Assays Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the neuroscience antibodies & assays market are Abcam plc, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Merck KGaA, Rockland Immunochemicals Inc., GenScript Biotech Corporation, Santa Cruz Biotechnology Inc., Wak-Chemie Medical GmbH, Epitope Diagnostics Inc., Agilent Technologies, Bio-Techne Corporation, Creative Diagnostics, Enzo Life Sciences Inc., Jackson ImmunoResearch Laboratories Inc., Novus Biologicals LLC, OriGene Technologies Inc., Proteintech Group Inc., R&D Systems Inc., RayBiotech Inc., StressMarq Biosciences Inc., Synaptic Systems GmbH, Tocris Bioscience, Alomone Labs Ltd., AnaSpec Inc., Antibodies.com, Antibody Solutions, Arbor Assays, Uscn Life Science Inc., Zymo Research Corp., AAT Bioquest Inc., Abbexa Ltd., ACROBiosystems Inc., Active Motif Inc., AdipoGen Life Sciences, Advanced Targeting Systems Inc., AgriSera AB
View The Full Neuroscience Antibodies & Assays Market Report:
Neuroscience Antibodies & Assays Market Geographic Distribution And Regional Opportunities
North America was the largest region in the neuroscience antibodies & assays market in 2025. The regions covered in the neuroscience antibodies & assays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
